JP5694382B2 - Composition for preventing hair loss and promoting hair growth comprising a dibenzo-p-dioxin derivative - Google Patents
Composition for preventing hair loss and promoting hair growth comprising a dibenzo-p-dioxin derivative Download PDFInfo
- Publication number
- JP5694382B2 JP5694382B2 JP2012551913A JP2012551913A JP5694382B2 JP 5694382 B2 JP5694382 B2 JP 5694382B2 JP 2012551913 A JP2012551913 A JP 2012551913A JP 2012551913 A JP2012551913 A JP 2012551913A JP 5694382 B2 JP5694382 B2 JP 5694382B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- composition
- formula
- scalp
- dibenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 67
- 230000003779 hair growth Effects 0.000 title claims description 17
- 230000003658 preventing hair loss Effects 0.000 title claims description 12
- 230000001737 promoting effect Effects 0.000 title claims description 12
- 150000004827 dibenzo-1,4-dioxins Chemical class 0.000 title description 16
- 210000004209 hair Anatomy 0.000 claims description 79
- 239000000126 substance Substances 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 25
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical class C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 claims description 17
- 239000002453 shampoo Substances 0.000 claims description 16
- -1 dihydroxyphenyl Chemical group 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000001256 tonic effect Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 210000004761 scalp Anatomy 0.000 description 63
- 230000000694 effects Effects 0.000 description 34
- 208000001840 Dandruff Diseases 0.000 description 27
- 206010061218 Inflammation Diseases 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 22
- 230000004054 inflammatory process Effects 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 230000036541 health Effects 0.000 description 15
- 208000003251 Pruritus Diseases 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 13
- 230000003646 hair health Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005722 itchiness Effects 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241000555676 Malassezia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000118 hair dye Substances 0.000 description 4
- 230000003699 hair surface Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000036758 dandruff formation Effects 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003806 hair structure Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 0 C*CC(*(C)*1(CC1)C1=*C(CC*[C@@]2O*)O*)[*@](C)C1=C2[O+]*1C=C(*)[C@](C)CC1O* Chemical compound C*CC(*(C)*1(CC1)C1=*C(CC*[C@@]2O*)O*)[*@](C)C1=C2[O+]*1C=C(*)[C@](C)CC1O* 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 241001291477 Malassezia restricta Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000008798 inflammatory stress Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical group O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000243681 Eisenia bicyclis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UHFFFAOYSA-N catechin Chemical compound OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000037389 hair physiology Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、頭皮および毛髪の健康を維持および改善させるジベンゾ−p−ジオキシン誘導体を含む組成物に関する。 The present invention relates to compositions comprising dibenzo-p-dioxin derivatives that maintain and improve the health of the scalp and hair.
頭皮および毛髪によって形成される空間は、高温多湿で微生物が生息するに適した環境を形成する。適切な衛生管理および生活習慣によって健康が維持される頭皮および毛髪組職は、血液循環、代謝作用、免疫作用などの均衡を図ることで、有害菌の繁殖を適切に抑制する。しかし、ホルモンの不均衡、各種ストレス、衛生管理の不備などの要因によって前記のような均衡が崩れると、頭皮および毛髪に多様な病理学的現象が発生することがある。例えば、頭皮および毛髪の表面組職に有害菌が繁殖して炎症反応が増加し、酸化ストレスが増加すると、頭皮および毛根の周辺に組職破壊、血液循環不良、細胞生長抑制、アレルギー現象などが現れる。これらの現象は、結局、脱毛、毛髪生長抑制、フケの過度の生成、頭皮炎症、痒み症などの原因となる。このような深刻な症状以外にも、前記のような頭皮および毛髪の特殊な環境は毛髪の表面を汚染させやすくすることにより、毛髪による美的外観を損なう。つまり、健康な状態においても、頭皮から分泌される汗、皮脂、その他のできもの、微生物などによって毛髪の表面が汚染し、毛髪の色沢、触感および匂いの質が低下しやすいため、前記のような病理学的条件でこのような汚染現象はさらに加速化する。 The space formed by the scalp and hair forms an environment suitable for inhabiting microorganisms at high temperature and humidity. A scalp and hair organization whose health is maintained by appropriate hygiene management and lifestyle habits appropriately suppresses the growth of harmful bacteria by balancing blood circulation, metabolic action, immune action, and the like. However, when the above-mentioned balance is lost due to factors such as hormonal imbalance, various stresses, and poor hygiene management, various pathological phenomena may occur in the scalp and hair. For example, when harmful bacteria propagate on the surface structure of the scalp and hair and the inflammatory response increases and oxidative stress increases, tissue destruction, poor blood circulation, cell growth suppression, allergic phenomena, etc. occur around the scalp and hair root. appear. These phenomena eventually cause hair loss, hair growth inhibition, excessive production of dandruff, scalp inflammation, itching and the like. In addition to such serious symptoms, the special environment of the scalp and hair described above impairs the aesthetic appearance of the hair by facilitating contamination of the hair surface. In other words, even in a healthy state, the surface of the hair is easily contaminated by sweat, sebum, other products, microorganisms, etc. secreted from the scalp, and the hair color, touch and odor quality are likely to deteriorate. Such pathological conditions further accelerate the contamination phenomenon.
頭皮と毛髪の生理作用の恒常性を破る根本的な要因としては、ホルモンの不均衡、多様なストレスおよび衛生管理の不備などを挙げることができる。これらの要因は、人体と多様な条件で相互作用することにより、頭皮と毛髪に複雑な生理学的・生化学的不均衡をもたらし、究極的に多様な頭皮および毛髪に関連する症状を発生させる。 Fundamental factors that break the homeostasis of scalp and hair physiology include hormonal imbalances, various stresses and poor hygiene. These factors interact with the human body in a variety of conditions, resulting in complex physiological and biochemical imbalances in the scalp and hair, ultimately generating a variety of scalp and hair related symptoms.
一方、これまで開発された頭皮および毛髪の健康改善を追求する主な製品は、頭皮および毛髪の健康に影響を及ぼす1つの要因の抑制のみを追求することで深刻な副作用を伴うことが報告されている。例えば、遺伝的な要因によって男性ホルモンのDHTが過多発生する脱毛現象を防ぐためにDHT合成酵素抑制剤が開発されて販売されているが、副作用が大きく、頭皮と毛髪の生理の恒常性を根本的に解決するには限界があった。また、フケを低減させるために抗真菌剤を用いる製品が発売されているが、同じく副作用の恐れがあり、根本的な毛髪の健康改善には限界がある。また、人体安全性と全般的な健康を追求する点で漢方を応用した複合生薬処方が開発され製品化されている。しかし、このような製品は、合成成分を用いた製品に比べて人体安全性は優れているが、標準化が難しく、効果と複合成分との相関関係を導き出すことが困難であるため、効果を極大化させ、体系的に発展させるには限界があった。そのため、安全性と標準化が容易でありながらも、頭皮と毛髪の健康を害する主な要因を効果的に制御可能な成分の開発が要求されている。 On the other hand, the main products that have been developed so far to improve the health of the scalp and hair are reported to have serious side effects by pursuing only the suppression of one factor affecting the health of the scalp and hair. ing. For example, DHT synthase inhibitors have been developed and marketed to prevent hair loss, which is caused by excessive male hormone DHT due to genetic factors, but they have significant side effects and fundamentally maintain the physiological stability of the scalp and hair. There were limits to solving this problem. In addition, products that use antifungal agents to reduce dandruff are on the market, but there is also a risk of side effects, and there is a limit to fundamentally improving hair health. In addition, compound herbal prescriptions using Kampo have been developed and commercialized in pursuit of human safety and general health. However, these products have better human safety than products using synthetic ingredients, but they are difficult to standardize and it is difficult to derive the correlation between the effects and the composite ingredients, so the effects are maximized. There was a limit to the development and systematic development. Therefore, there is a demand for the development of components that can easily control the main factors that are harmful to the health of the scalp and hair, while being safe and standardized easily.
本発明は、従来技術の限界を克服し、より効果的に頭皮と毛髪の健康を改善するためのものであって、頭皮および毛髪の健康維持および改善において核心的な要素と言える抗菌、抗酸化および抗炎効果にすべて優れていながらも、毛髪との親和力も優れた成分を含むことにより、低濃度でも頭皮および毛髪の健康を効果的に維持改善させ、非常に安全な頭皮および毛髪健康改善用組成物を提供することを目的とする。 The present invention is intended to overcome the limitations of the prior art and more effectively improve the health of the scalp and hair, and is an antibacterial and antioxidant that can be said to be a core element in maintaining and improving the health of the scalp and hair In addition, it contains all ingredients with excellent anti-inflammation effect but also good affinity with hair, so that it can effectively maintain and improve the health of the scalp and hair even at low concentrations, and is very safe for improving scalp and hair health. An object is to provide a composition.
本発明は、ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体を有効成分として含む頭皮および毛髪健康改善用組成物を提供する。 The present invention provides a composition for improving scalp and hair health comprising a dibenzo-p-dioxine derivative as an active ingredient.
前記ジベンゾ−p−ジオキシン誘導体は、下記化学式1〜10で表される化合物からなる群より選択される1種以上の化合物であり得る。 The dibenzo-p-dioxin derivative may be one or more compounds selected from the group consisting of compounds represented by the following chemical formulas 1 to 10.
前記化学式1〜10において、Rは、それぞれ独立に、水素、C1〜C5のアルキル、C2〜C5のアルケニル、フェニル、C7〜C12のフェニルアルキル、C2〜C20のアルカノイル、C3〜C20のアルケノイル、ヒドロキシフェニル、ジヒドロキシフェニルまたはトリヒドロキシフェニルである。 In the chemical formulas 1 to 10, each R is independently hydrogen, C1 to C5 alkyl, C2 to C5 alkenyl, phenyl, C7 to C12 phenylalkyl, C2 to C20 alkanoyl, C3 to C20 alkenoyl, hydroxy. Phenyl, dihydroxyphenyl or trihydroxyphenyl.
本発明のジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体を含む頭皮および毛髪健康改善用組成物は、頭皮および毛髪で発生するフケ菌(Malassezia resista)の繁殖、酸化ストレス、炎症反応を安全でありながらも効果的に抑制することにより、脱毛予防、毛髪の生長促進、フケ防止、頭皮炎症の改善、頭皮の痒み症の抑制に優れた効果を提供する。また、本発明の組成物は、毛髪の表面の破壊および微生物による汚染を効果的に防止することにより、毛髪の外観を健康で美しく維持させる効果を提供する。 The composition for improving scalp and hair health containing the dibenzo-p-dioxine derivative of the present invention is safe against the growth, oxidative stress, and inflammatory reaction of dander fungus (Malassezia resista) occurring in the scalp and hair. However, by effectively suppressing it, it provides excellent effects in preventing hair loss, promoting hair growth, preventing dandruff, improving scalp inflammation, and suppressing scalp itch. In addition, the composition of the present invention provides an effect of maintaining the appearance of hair in a healthy and beautiful manner by effectively preventing the destruction of the hair surface and contamination by microorganisms.
本発明は、ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体を有効成分として含む頭皮および毛髪健康改善用組成物に関するものである。 The present invention relates to a scalp and hair health improving composition comprising a dibenzo-p-dioxine derivative as an active ingredient.
本発明者らは、頭皮および毛髪の健康を害する生理、生化学的要因であるフケ菌、炎症、酸化ストレスの作用が互いに複合的に相乗作用するため、1つの要因の制御だけでは頭皮および毛髪の健康を効果的かつ安全に改善させることが困難であるということを認識し、有害菌、炎症反応および酸化ストレスの同時的かつ効果的な制御が可能な成分または組成を見出すことを目標として研究を進めた。また、持続的な使用から発生し得る生理的不均衡を予防可能な、絶対的な安全性が確保される成分または組成を見出すことを目標とした。 Since the effects of physiology, biochemical factors, dandruff bacteria, inflammation, and oxidative stress, which harm the health of the scalp and hair, are combined and synergistic with each other, the inventors of the present invention have only one control of the scalp and hair. Recognizing that it is difficult to effectively and safely improve the health of human beings, research with the goal of finding ingredients or compositions that can simultaneously and effectively control harmful fungi, inflammatory reactions and oxidative stress Advanced. It was also aimed to find a component or composition with absolute safety that can prevent physiological imbalances that may arise from sustained use.
このような目標を達成するために、本発明者らは、刺激性/毒性のない天然物来由の構造を有する成分であって、毛髪および頭皮組職との親和力が優れると同時に、抗酸化、抗炎、抗菌作用が優れ、毛髪および頭皮組職において、有害菌の繁殖、炎症の発生、酸化ストレスをより効果的に長時間遮断可能な成分を見出すために努力を重ねた結果、ジベンゾ−p−ジオキシン骨格を有する天然化合物がこのような条件を非常によく満たすことを見出し、本発明に至った。 In order to achieve such a goal, the present inventors have an ingredient having a structure derived from a natural product that is not irritating / toxic and has an excellent affinity for hair and scalp tissue, and at the same time, an antioxidant. As a result of efforts to find a component that can effectively block harmful bacterial growth, inflammation, and oxidative stress in hair and scalp tissue for a long time in the hair and scalp organization, dibenzo- It has been found that a natural compound having a p-dioxin skeleton satisfies such a condition very well, and has led to the present invention.
脱毛、毛髪生長抑制、フケの生成、炎症、痒み症などの根本的要因、つまり、ホルモンの不均衡、生活習慣による多様なストレス要因、衛生状態による二次的有害菌の発生、炎症反応、酸化ストレスなどの要因が増加すると、これらの作用がより複合的に作用し、アレルギー反応、血液循環不良、細胞代謝および生長抑制作用が現れる。そして、これらの原因によって、結局、脱毛、毛髪生長抑制、フケの生成、炎症、痒み症などの現象が発生する。 Fundamental factors such as hair loss, hair growth inhibition, dandruff formation, inflammation, itchiness, that is, hormonal imbalance, various stress factors due to lifestyle, occurrence of secondary harmful bacteria due to hygiene, inflammatory reaction, oxidation When factors such as stress increase, these actions act in a more complex manner, and allergic reactions, poor blood circulation, cell metabolism and growth suppression appear. Then, due to these causes, phenomena such as hair loss, suppression of hair growth, generation of dandruff, inflammation, and itchiness occur.
前記二次的要因の一つとして、フケの原因となる菌(Malassezia restrica)が最近知られるようになった(Christina M.Gemmer,Thomas L.Dawson Jr,et al.,Journal of Clinical Microbiology,Sept Vol.40,No.9,p3350−3357(2002))。この菌は、頭皮に正常菌叢の一部として存在し、ストレス、気候の変化、汗、飲食などの環境的誘発要因によって過大増殖した場合、フケ、痒み症、脂漏性皮膚炎を誘発させることが報告された(Bergbrant I.M.Seborrhoeic dermatitis and Pityrosporum yeasts.Current Topics in Medical Mycology.6:95−112(1995))。また、フケが多く発生すると、痒みなどによって頭皮を過度に擦るようになり、これによって傷ができたり、場合によっては、二次的炎症を起こしたりし、脱毛の原因になったりもする。現在、フケ治療剤として、抗真菌剤のケトコナゾール(ketoconazole)、亜鉛ピリチオン(zinc pyrithion)、イトラコナゾール(itraconazole)、ピロクトンオラミン(Piroctone Olamine)などが主に使用されているが、前記抗真菌剤は、フケの治療によい効果を示すのに対し、人為的に合成された物質であるため、人体の安全性に対する疑問が提起されている。本発明者らは、持続的な研究により、ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体がMalassezia restrica菌を効果的に制御しながらも安全であることを確認した。 As one of the secondary factors, a dandruff-causing bacterium (Malassezia restrica) has recently been known (Christina M. Gemmer, Thomas L. Dawson Jr, et al., Journal of Clinical Microbiol, Vol.40, No. 9, p3350-3357 (2002)). This fungus is present in the scalp as part of the normal flora and, when over-proliferated by environmental triggers such as stress, climate change, sweating, eating and drinking, induces dandruff, itching, and seborrheic dermatitis (Bergbrant IM Seborrhoeic dermatitis and Pytrosporum yeasts. Current Topics in Medical Mycology. 6: 95-112 (1995)). In addition, when a large amount of dandruff occurs, the scalp is excessively rubbed due to itching or the like, which can cause scratches or, in some cases, cause secondary inflammation and cause hair loss. Currently, antifungal agents ketoconazole, zinc pyrithione, itraconazole, piroctone olamine, etc. are mainly used as antidandruff agents. Although it is effective for the treatment of dandruff, it is an artificially synthesized substance, so the question of human safety has been raised. The present inventors have confirmed through continuous research that dibenzo-p-dioxine derivatives are safe while effectively controlling Malassezia restrica.
また、前述した二次的要因の一つである炎症反応は、有害菌の刺激によっても発生するが、これとは関係なく、高カロリーと運動不足で特徴付けられる、西欧化された生活習慣による代謝性症侯群によっても慢性的に発生し、精神的なストレスやショックによって一時的に発生することもある。炎症反応は、組職の退行化を加速化させ、細胞生長を抑制し、免疫体系を過度に敏感にすることにより、アレルギー現象をさらに刺激するなど、頭皮および毛髪組職の健康を害する。本発明者らは、ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体が炎症を効果的に制御しながらも安全であることを確認した。 In addition, the inflammatory reaction, which is one of the secondary factors mentioned above, is also caused by the stimulation of harmful bacteria, but regardless of this, it is due to westernized lifestyle habits characterized by high calories and lack of exercise. It also occurs chronically in metabolic syndrome and may occur temporarily due to mental stress or shock. Inflammatory reactions damage the health of the scalp and hair organization, such as accelerating tissue regression, suppressing cell growth, and making the immune system excessively sensitive, further stimulating allergic phenomena. The inventors have confirmed that dibenzo-p-dioxine derivatives are safe while effectively controlling inflammation.
さらに、前記二次的要因の一つである酸化ストレスは、紫外線、公害物質の作用によって発生し、頭皮組職のDNA、細胞膜、蛋白質を攻撃して毛髪および頭皮組職を破壊し、炎症を起こすことにより、頭皮および毛髪の健康を害する。本発明者らは、ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体が酸化ストレスを効果的に制御しながらも安全であることを確認した。 Furthermore, oxidative stress, which is one of the secondary factors, is generated by the action of ultraviolet rays and pollutants, and attacks the scalp tissue DNA, cell membranes and proteins to destroy the hair and scalp tissue, causing inflammation. Waking up harms the health of the scalp and hair. The present inventors have confirmed that a dibenzo-p-dioxine derivative is safe while effectively controlling oxidative stress.
また、このような二次的要因は、生活習慣や環境から持続的に供給されて継続して毛髪および頭皮を刺激するため、これらの要因が頭皮および毛髪に作用することを最小化させることができる方法、例えば、これらの有害要因を制御可能で、同時に、頭皮および毛髪にコーティングされてより効果的に防御可能な成分の開発が必要になる。本発明者らは、ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体が毛髪親和力に非常に優れていることを確認した。 In addition, since these secondary factors are continuously supplied from lifestyle and environment and continuously stimulate the hair and scalp, it is possible to minimize the effect of these factors on the scalp and hair. There is a need for the development of ingredients that can be controlled, such as those that can control these detrimental factors and at the same time be coated on the scalp and hair to more effectively protect. The present inventors have confirmed that dibenzo-p-dioxine derivatives are very excellent in hair affinity.
前記要因(有害菌、炎症、酸化ストレス)は、互いに複合的に相乗作用して持続されてさらに悪化するという悪循環をもたらすことにより、脱毛の促進、毛髪生長抑制、フケの過度の生成、頭皮炎症、痒み症などの現象を引き起こす。したがって、前記のような複合的な要因に対してすべて優れた効果を提供するジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体は、脱毛の促進、毛髪生長抑制、フケの過度の生成、頭皮炎症、痒み症などに非常に優れた効果を提供する。 The above factors (harmful bacteria, inflammation, oxidative stress) promote a hair loss, suppress hair growth, excessive production of dandruff, scalp inflammation by bringing about a vicious cycle in which they synergize and sustain each other in a complex manner. Cause itchiness and other phenomena. Therefore, the dibenzo-p-dioxine derivative, which provides all the excellent effects on the complex factors as described above, promotes hair loss, suppresses hair growth, excessive production of dandruff, scalp Provides very good effects on inflammation and itchiness.
本発明の頭皮および毛髪健康改善用組成物は、既存の抗菌、抗酸化、抗炎活性を有する化合物が刺激性および毒性が強く、繰り返し使用すると、頭皮の健康に悪影響を及ぼしていたのとは異なり、毒性や刺激性がないだけでなく、むしろ他の成分による刺激も緩和させる機能を提供するという特徴を有する。また、頭皮と毛髪組職との親和力により、少量の使用量でも頭皮と毛髪組職に抗菌、抗酸化、抗炎機能を集中することが可能であるため、危険な要因(微生物、活性酸素、炎症反応)を効果的に根本的に遮断するか除去するという特徴を有する。さらに、既存の抗菌剤は、毒性および刺激性によって頭皮および毛髪組職にとどまる時間を最小化しなければならず、耐性も発生させる問題があったが、本発明の組成物は、毒性および刺激性がないため、頭皮および毛髪組職で微生物が繁殖できないように抗菌層を形成しても問題がなく、耐性も発生しないという特徴を有する。 In the composition for improving scalp and hair health of the present invention, the existing compounds having antibacterial, antioxidant and anti-inflammatory activities are highly irritating and toxic. Unlike it, it is not only toxic and irritating, but rather has the feature of providing a function to alleviate irritation by other ingredients. In addition, the affinity between the scalp and the hair structure allows the antibacterial, antioxidant, and anti-inflammatory functions to be concentrated on the scalp and hair structure even with a small amount of use, so dangerous factors (microorganisms, active oxygen, It has the feature of effectively blocking or eliminating the inflammatory reaction). Furthermore, while the existing antibacterial agents have had the problem of having to minimize the time spent in the scalp and hair organization due to toxicity and irritation, there has also been a problem of developing resistance, the composition of the present invention is toxic and irritating Therefore, there is no problem even if an antibacterial layer is formed so that microorganisms cannot propagate in the scalp and hair structure, and no resistance is generated.
本発明において、前記ジベンゾ−p−ジオキシン誘導体は、下記化学式1〜10で表される化合物からなる群より選択される1種以上の化合物であり得る。 In the present invention, the dibenzo-p-dioxin derivative may be one or more compounds selected from the group consisting of compounds represented by the following chemical formulas 1 to 10.
前記化学式1〜10において、Rは、それぞれ独立に、水素、C1〜C5のアルキル、C2〜C5のアルケニル、フェニル、C7〜C12のフェニルアルキル、C2〜C20のアルカノイル、C3〜C20のアルケノイル、ヒドロキシフェニル、ジヒドロキシフェニルまたはトリヒドロキシフェニルである。 In the chemical formulas 1 to 10, each R is independently hydrogen, C1 to C5 alkyl, C2 to C5 alkenyl, phenyl, C7 to C12 phenylalkyl, C2 to C20 alkanoyl, C3 to C20 alkenoyl, hydroxy. Phenyl, dihydroxyphenyl or trihydroxyphenyl.
前記Rは、それぞれ独立に、水素;メチル;エテニル;ベンジル;アセチルまたはオレオイル(oleoyl);4−ヒドロキシフェニル;2,4−ヒドロキシフェニル;または2,4,6−トリヒドロキシフェニルであることが好ましい。より好ましくは水素である。 Each R is independently hydrogen; methyl; ethenyl; benzyl; acetyl or oleoyl; 4-hydroxyphenyl; 2,4-hydroxyphenyl; or 2,4,6-trihydroxyphenyl. preferable. More preferred is hydrogen.
本発明の頭皮および毛髪健康改善用組成物において、ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体は、前記化学式3、化学式5、化学式6および化学式8からなる群より選択される2種以上の化合物で構成されるものであり得、この時、前記化学式3、5、6および8において、R=Hであることが好ましい。 In the scalp and hair health improving composition of the present invention, the dibenzo-p-dioxine derivative is at least two selected from the group consisting of Chemical Formula 3, Chemical Formula 5, Chemical Formula 6, and Chemical Formula 8. In this case, in Formulas 3, 5, 6 and 8, it is preferable that R = H.
前記ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体は、前記誘導体の総重量に対して、化学式3の化合物10〜60重量%、化学式5の化合物15〜60重量%、化学式6の化合物10〜40重量%および化学式8の化合物5〜30重量%を含んで構成され得る。 The dibenzo-p-dioxine derivative is 10 to 60% by weight of the compound of Formula 3, 15 to 60% by weight of the compound of Formula 5, and 10 of the compound of Formula 6 with respect to the total weight of the derivative. May be comprised of ˜40% by weight and 5-30% by weight of the compound of formula 8.
また、前記ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体は、誘導体の総重量に対して、化学式3の化合物12〜38重量%、化学式5の化合物18〜57重量%、化学式6の化合物10〜30重量%および化学式8の化合物10〜30重量%を含んで構成されることがより好ましい。 In addition, the dibenzo-p-dioxine derivative is 12 to 38% by weight of the compound of Formula 3, 18 to 57% by weight of the compound of Formula 5, and the compound of Formula 6 with respect to the total weight of the derivative. More preferably, it comprises 10 to 30% by weight and 10 to 30% by weight of the compound of formula 8.
前記ジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体は、前記化学式3、化学式5、化学式6および化学式8からなる群より選択される2種以上の化合物のほか、前記化学式1、化学式2、化学式4、化学式9および化学式10からなる群より選択される1種以上の化合物をさらに含んで構成され得る。この場合、前記化学式1、化学式2、化学式4、化学式9および化学式10からなる群より選択される1種以上の化合物は、前記誘導体の総重量に対して、0.1〜50重量%含まれることが好ましい。 The dibenzo-p-dioxine derivative includes two or more compounds selected from the group consisting of the chemical formula 3, the chemical formula 5, the chemical formula 6, and the chemical formula 8, the chemical formula 1, the chemical formula 2, One or more compounds selected from the group consisting of Chemical Formula 4, Chemical Formula 9, and Chemical Formula 10 may be further included. In this case, one or more compounds selected from the group consisting of Chemical Formula 1, Chemical Formula 2, Chemical Formula 4, Chemical Formula 9, and Chemical Formula 10 are included in an amount of 0.1 to 50% by weight based on the total weight of the derivative. It is preferable.
本発明の頭皮および毛髪健康改善用組成物は、医学的用途としてのみならず、化粧料として使用されてもよい。例えば、本発明の頭皮および毛髪健康改善用組成物は、脱毛防止および毛髪の生長促進用医薬品、脱毛防止および毛髪の生長促進機能を有する化粧品などを含む。前記化粧品は、具体的には、頭髪化粧品を意味し、シャンプー、リンス、ローション、トニック、エッセンス、せっけん、ジェル、ムースなどを挙げることができる。 The scalp and hair health improving composition of the present invention may be used not only as a medical use but also as a cosmetic. For example, the scalp and hair health improving composition of the present invention includes pharmaceuticals for preventing hair loss and promoting hair growth, cosmetics having functions for preventing hair loss and promoting hair growth, and the like. The cosmetics specifically mean hair cosmetics, and can include shampoo, rinse, lotion, tonic, essence, soap, gel, mousse and the like.
本発明の頭皮および毛髪健康改善用組成物は、頭皮や毛髪に直接適用する外用剤の形態で投与可能であり、医薬組成物および化粧料組成物の各分野で通常使用される賦形剤と共に多様な剤形を形成することができる。 The scalp and hair health improving composition of the present invention can be administered in the form of an external preparation applied directly to the scalp and hair, together with excipients commonly used in the fields of pharmaceutical compositions and cosmetic compositions. A variety of dosage forms can be formed.
本発明の頭皮および毛髪健康改善用組成物に含まれるジベンゾ−p−ジオキシン(dibenzo−p−dioxine)誘導体の1日の使用量は、1〜100mg程度が好ましい。使用量は前記範囲に限定されるものではない。本発明の頭皮および毛髪健康改善用組成物は、脱毛予防、毛髪の生長促進、フケ防止、頭皮炎症の改善、頭皮の痒み症の抑制などの用途に使用可能である。また、前記組成物は、毛髪の表面の破壊および汚染を効果的に防止することにより、毛髪の表面の健康増進および毛髪の管理を容易にする用途にも使用可能である。 The daily usage of the dibenzo-p-dioxine derivative contained in the scalp and hair health improving composition of the present invention is preferably about 1 to 100 mg. The amount used is not limited to the above range. The composition for improving scalp and hair health of the present invention can be used for purposes such as preventing hair loss, promoting hair growth, preventing dandruff, improving scalp inflammation, and suppressing scalp itch. The composition can also be used for the purpose of facilitating hair surface health promotion and hair management by effectively preventing the destruction and contamination of the hair surface.
本発明の頭皮および毛髪健康改善用組成物に含まれるジベンゾ−p−ジオキシン誘導体は、通常のすべての方法によって得ることができ、市販の試薬を用いて合成することもでき、天然物、特に、海藻類から抽出および分離して得ることもできる。 The dibenzo-p-dioxin derivative contained in the scalp and hair health improving composition of the present invention can be obtained by all ordinary methods, can be synthesized using commercially available reagents, and natural products, in particular, It can also be obtained by extraction and separation from seaweed.
以下、実施例を用いて本発明をより詳細に説明する。しかし、下記の実施例は本発明をより具体的に説明するためのものであって、本発明の範囲が下記の実施例によって限定されるものではない。下記の実施例は、本発明の範囲内で当業者によって適切に修正、変更可能である。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the following examples are for explaining the present invention more specifically, and the scope of the present invention is not limited by the following examples. The following embodiments can be appropriately modified and changed by those skilled in the art within the scope of the present invention.
実施例1:ジベンゾ−p−ジオキシン誘導体の分離精製
1−1:褐藻類からのポリフェノール混合物の抽出
大黄(Eisenia bicyclis、1kg)を、新鮮な状態で、搾汁機を用いて繊維質を除去した後、95%のエチルアルコール(4L)を追加し、常温で30分間撹拌して溶液のみを濾過した後、乾燥し、58gの褐色粉末を得た。得られた乾燥粉末を20倍量の蒸溜水(50℃)に溶解させた後、PVPP(Polyvinylpyrrolidone)樹脂(前記乾燥粉末の重量の10倍)と混合して撹拌した後(50℃、1hr)、溶液を濾過して除去し、十分な量の蒸溜水(重量比でPVPP樹脂の5倍以上)で洗浄した。洗浄されたPVPP樹脂に95%のエタノール(重量比でPVPP樹脂の3倍量)を加え、常温で30分間撹拌した後、濾過し、溶液を取って乾燥し、8gの黒褐色粉末を得た。フォリン試薬を用いてポリフェノールの総含有量を測定した結果、96.7%となった。
Example 1: Separation and purification of dibenzo-p-dioxin derivative 1-1: Extraction of polyphenol mixture from brown algae Daisen (Eisenia bicyclis, 1 kg) was fresh and fiber was removed using a squeezer. Thereafter, 95% ethyl alcohol (4 L) was added, and the mixture was stirred at room temperature for 30 minutes to filter only the solution, followed by drying to obtain 58 g of a brown powder. After the obtained dry powder was dissolved in 20 times the amount of distilled water (50 ° C.), it was mixed with PVPP (Polyvinylpyrrolidone) resin (10 times the weight of the dry powder) and stirred (50 ° C., 1 hr). The solution was removed by filtration and washed with a sufficient amount of distilled water (more than 5 times the weight of PVPP resin by weight). 95% ethanol (3 times the amount of PVPP resin by weight) was added to the washed PVPP resin, stirred for 30 minutes at room temperature, filtered, and the solution was dried to obtain 8 g of a dark brown powder. As a result of measuring the total content of polyphenols using a forin reagent, it was 96.7%.
1−2:精製されたポリフェノール混合物からのジベンゾ−p−ジオキシン誘導体の分離
前記実施例1で得られたポリフェノール混合物を、0.2μmの膜濾過紙で濾過し、高速液体クロマトグラフィーにローディング(loading)した。高速液体クロマトグラフィーにおいて、カラムはHP ODS Hypersilカラムを、溶媒としては蒸溜水とメタノールを使用し、溶媒の供給は、1.0ml/分の流速で、メタノール15%から70%まで、30分間にわたり、線形勾配(linear gradient)をかけて10種の活性物質を分離した。各化合物は、化学式1〜10のジベンゾ−p−ジオキシン誘導体であることを確認した。
1-2: Separation of Dibenzo-p-dioxin Derivative from Purified Polyphenol Mixture The polyphenol mixture obtained in Example 1 is filtered through a 0.2 μm membrane filter paper and loaded into high performance liquid chromatography. )did. In high performance liquid chromatography, the column is a HP ODS Hypersil column, distilled water and methanol are used as solvents, and the solvent is supplied at a flow rate of 1.0 ml / min from 15% to 70% methanol over 30 minutes. Ten active substances were separated by applying a linear gradient. Each compound was confirmed to be a dibenzo-p-dioxin derivative represented by Chemical Formulas 1-10.
前記化学式1〜10において、Rは、水素である。 In the chemical formulas 1 to 10, R is hydrogen.
実施例2:毛髪親和力、抗酸化、抗炎および抗菌力の評価実験
実施例1で分離されたジベンゾ−p−ジオキシン誘導体と、抗酸化、抗炎または抗菌力に優れていることがよく知られた天然成分である、ケルセチン(quercetin)、EGCG(Epigallocatechin gallate)、カテキン(catechin)およびサリチル酸とに対して、毛髪親和力、抗酸化力、抗炎活性、抗菌力を比較評価し、その結果を下記表1に示した。
Example 2: Experiments for evaluating hair affinity, antioxidant, anti-inflammatory and antibacterial activity It is well known that the dibenzo-p-dioxin derivative isolated in Example 1 is excellent in antioxidant, anti-inflammatory or antibacterial activity. Compared with natural ingredients quercetin, EGCG (Epigallocatechin gallate), catechin and salicylic acid, the hair affinity, antioxidant power, anti-inflammatory activity and antibacterial power were compared and evaluated. It is shown in Table 1.
2−1:毛髪親和力の評価
実施例1で分離されたジベンゾ−p−ジオキシン誘導体の毛髪との親和力の評価を、次のように実施した。
2-1: Evaluation of hair affinity The evaluation of the affinity of the dibenzo-p-dioxin derivative separated in Example 1 with hair was performed as follows.
男性5人および女性5人の理髪によって得られた毛髪(約1cmの長さ)をそれぞれ10gずつ計100g確保し、1mMのTX−100水溶液(1L)に入れて常温で撹拌した後、洗浄液を除去し、残りの毛髪を10Lの蒸溜水を用いて洗浄した後、40℃の対流式オーブン(Convection Oven)で30分間乾燥した。一方、実施例1で分離されたジベンゾ−p−ジオキシン誘導体それぞれの試料をDMSOに溶かし、0.1wt%となるようにサンプル溶液を作った。10mLのリン酸緩衝溶液(pH7.0、0.1mM)にそれぞれ30マイクロリットルのサンプル溶液を添加して十分に混合した後、それぞれ1gの用意された毛髪を添加し、40℃で10分間激しく撹拌した。毛髪が添加されていない各サンプル溶液に対しても、これと同様の過程を行った。それぞれの溶液から溶液のみを抽出し、それぞれの吸光度を254nm、25℃で測定した。 A total of 100 g of hair (about 1 cm length) obtained by hairdressing of 5 men and 5 women was secured, placed in a 1 mM TX-100 aqueous solution (1 L), stirred at room temperature, and then washed with a washing solution. The hair was removed and the remaining hair was washed with 10 L of distilled water, and then dried in a convection oven at 40 ° C. for 30 minutes. On the other hand, each sample of the dibenzo-p-dioxin derivative separated in Example 1 was dissolved in DMSO to prepare a sample solution so as to be 0.1 wt%. Add 30 microliters of each sample solution to 10 mL of phosphate buffer solution (pH 7.0, 0.1 mM) and mix well, then add 1 g of each prepared hair and vigorously at 40 ° C. for 10 minutes. Stir. The same process was performed for each sample solution to which no hair was added. Only the solution was extracted from each solution, and each absorbance was measured at 254 nm and 25 ° C.
各サンプルに対して、毛髪との相互作用が存在しない状態での溶液の吸光度をA100とし、相互作用がある状態での吸光度をAとし、次の式を用いて各サンプルの毛髪親和力を計算し、下記表1に示した。
毛髪親和力(%)=100×(A100−A)/A100
For each sample, the absorbance of the solution in the absence of interaction with hair is A100, the absorbance in the presence of interaction is A, and the hair affinity of each sample is calculated using the following formula: The results are shown in Table 1 below.
Hair affinity (%) = 100 × (A100−A) / A100
2−2:抗酸化力の評価
実施例1で分離されたジベンゾ−p−ジオキシン誘導体に対する抗酸化力の評価を、次のように実施した。
2-2: Evaluation of antioxidant power The antioxidant power of the dibenzo-p-dioxin derivative separated in Example 1 was evaluated as follows.
DPPH試薬2mgを正確に秤量し、EtOH15mlに溶かした溶液1.2mlに、さらにEtOH3mlとDMSO0.5mlを混合し、DPPH溶液を製造した。そして、評価しようとする各試料をDMSOに溶かし、100μg/mlの濃度となるようにそれぞれの試料溶液を製造した。それぞれの試料溶液50μlと製造したDPPH溶液を混合し、10分間常温で反応させた後、518nmで吸光度を測定した。試料を添加していない対照群の吸光度をA0、試料を添加した溶液の吸光度をAとし、次の式によりDPPHラジカル消去活性を計算し、下記表1に示した。
DPPHラジカル消去活性(%)=100×(A0−A)/A0
2 mg of DPPH reagent was accurately weighed and 1.2 ml of a solution dissolved in 15 ml of EtOH was further mixed with 3 ml of EtOH and 0.5 ml of DMSO to prepare a DPPH solution. Then, each sample to be evaluated was dissolved in DMSO, and each sample solution was manufactured to have a concentration of 100 μg / ml. 50 μl of each sample solution and the produced DPPH solution were mixed and reacted at room temperature for 10 minutes, and then the absorbance was measured at 518 nm. The absorbance of the control group to which no sample was added was A0, the absorbance of the solution to which the sample was added was A, and the DPPH radical scavenging activity was calculated according to the following formula, and is shown in Table 1 below.
DPPH radical scavenging activity (%) = 100 × (A0−A) / A0
2−3:抗炎効果の評価
実施例1で分離されたジベンゾ−p−ジオキシン誘導体に対する抗炎効果の評価を、次のように実施した。マウスの大食細胞RAW264.7(Korean Cell Line Bank)を、DMEM(10%のウシ胎仔血清および1%のペニシリン/ストレプトマイシン)培地を用い、37℃、5%のCO2(fully humidified air)で培養した。培養された細胞を96ウェルプレート(200マイクロリットル/ウェル)に移し、LPS(E.coli、serotype055:B5、最終濃度1mg/mL)およびDMSOに溶かし、100μg/mlの濃度となるように予め作っておいたそれぞれの試料溶液(最終濃度=10μg/mL)を添加し、18時間培養した。LPSを処理していない溶液は陰性対照群、LPSを処理するものの、試料の代わりに生理食塩水を処理した溶液を陽性対照群として用いた。上澄液を分離した後、炎症反応の程度を表示するPGE2濃度(pg/mL)を、EIAキット製造会社(Cayman Chemical Co.)で提示したガイドに従って測定し、次の式により相対的な抗炎症効果(%)を計算し、下記表1に示した。
陽性対照群におけるPGE2濃度をCM、陰性対照群におけるPGE2濃度をC0、各試料の処理時におけるPGE2濃度をCとしたとき:
抗炎症効果(%)=100×(CM−C)/(CM−C0)
2-3: Evaluation of anti-inflammatory effect The anti-inflammatory effect with respect to the dibenzo-p-dioxin derivative isolate | separated in Example 1 was evaluated as follows. Murine macrophages RAW264.7 (Korean Cell Line Bank) were used in DMEM (10% fetal bovine serum and 1% penicillin / streptomycin) medium at 37 ° C., 5% CO 2 (fully humidified air). Cultured. The cultured cells are transferred to a 96-well plate (200 microliters / well), dissolved in LPS (E. coli, serotype 055: B5, final concentration 1 mg / mL) and DMSO, and prepared in advance to a concentration of 100 μg / ml. Each sample solution (final concentration = 10 μg / mL) was added and incubated for 18 hours. A solution not treated with LPS was treated as a negative control group, while LPS was treated, but a solution treated with physiological saline instead of the sample was used as a positive control group. After separating the supernatant, the PGE2 concentration (pg / mL) indicating the extent of the inflammatory reaction was measured according to the guide provided by the EIA kit manufacturer (Cayman Chemical Co.) and the relative anti The inflammatory effect (%) was calculated and shown in Table 1 below.
When the PGE2 concentration in the positive control group is CM, the PGE2 concentration in the negative control group is C0, and the PGE2 concentration during the treatment of each sample is C:
Anti-inflammatory effect (%) = 100 × (CM−C) / (CM−C0)
2−4.抗菌活性の測定
実施例1で分離されたジベンゾ−p−ジオキシン誘導体の抗菌力の評価を、平板培地拡散法(Agar diffusion method)を用いてフケの原因菌であるMalassezia restricta真菌に対する抑制活性を測定することによって行った。抗菌活性は、各試料が含有された紙ディスク(paper disk)を用いて平板培地拡散法で行った。まず、Malassezia restricta菌株を培養培地(Modified Leeming and Notman agar medium、0.1%のポリペプトン、2.0%のグルコース、5.0%の麦芽エキス(Malt extract)、2.0%のdesiccated ox bile、0.2%のグリセロール、1.0%のTween40および2.0%のagar in distilled water)を用いて36℃の条件で培養した。一方、それぞれの試料5mgをエタノール50μlに溶かした後、直径8mm、厚さ1.5mmの環状紙に全体的に均一に広がるように吸収させ、溶媒を完全に蒸発させた後、培養したマラセチア真菌の菌株が接種されたmLNA(Modified Leeming and Notman agar medium)平板培地に上げて抗菌活性試験を行った。前記のような培養条件で48時間培養した後、それぞれの試料が含浸された紙ディスクの周辺に形成された円形の生育阻止環の直径(mm)を測定した後、ディスクの直径(8mm)を引いて、2で除した値(阻害半径)で相対的な抗菌力を比較した。結果は、下記表1に示した。
実施例3:組成物の製造
前記実施例1および2から、ジベンゾ−p−ジオキシン誘導体が毛髪親和力、抗菌力、抗炎効果および抗酸化効果においてすべて優れていることを確認した。特に、毛髪親和力、抗菌力および抗炎効果は、他の天然物に比べて顕著に優れていた。抗酸化効果も最高水準であった。このような結果から、本発明のジベンゾ−p−ジオキシン誘導体は、それぞれ使用しても、頭皮と毛髪の健康改善に優れた効果を示すことが期待された。そして、それらの組み合わせを通じてより優れた効果を示すことが期待された。したがって、各活性に優れた成分を選定し、組成物1〜5を製造した。各組成物の化学的組成は、下記表2のとおりである。
実施例4:前記組成物の毛髪生長促進効果の評価
本発明にかかる組成物の毛髪生長効果をテストした。生後7週齢のマウス(C57BL/6)の背中部位の毛を除去し、背中部位の皮膚が綺麗なものを選んで物質群ごとに5匹ずつを選定し、毎日、前記実施例3の1〜5の組成物を、それぞれのマウスグループあたり150μlずつ、21日間塗布した。比較群としては、実施例2の比較試料のうち比較的優れた効果を示したEGCG、陰性対照群としては、何らかの試料も含まないようにして水/エタノール/1,3−ブチレングリコール(容積比:5/3/2)で構成された溶媒を使用した。塗布から23日後、新たに伸びた毛の重量を測定して陰性対照群と比較し、その結果を下記表3に示した。
表3から明らかなように、本発明にかかる組成物およびEGCGを含む場合、陰性対照群(水/エタノール/1,3−ブチレングリコール)を塗布した群より高い毛髪重量の平均値を示した。特に、毛髪親和力の高い成分が最小化された組成物5に比べて、毛髪親和力の高い成分が高く含有された組成物1〜4が全般的に高い毛髪成長促進効果があることを確認することができた。毛髪親和力、抗酸化力、抗炎および抗菌力の均衡を合わせた組成1が、毛髪成長促進効果に最も優れていた。 As apparent from Table 3, when the composition according to the present invention and EGCG were included, the average value of the hair weight was higher than that of the group to which the negative control group (water / ethanol / 1,3-butylene glycol) was applied. In particular, confirm that compositions 1 to 4 containing a high amount of hair affinity components generally have a high hair growth-promoting effect as compared to composition 5 in which a high hair affinity component is minimized. I was able to. Composition 1, which balanced the balance of hair affinity, antioxidant power, anti-flame and antibacterial power, was most excellent in promoting hair growth.
実施例5:前記組成物の頭皮炎症の緩和および抑制効果の測定
前記組成物の染毛剤の刺激による頭皮炎症の緩和および抑制効果を測定するために、MEST(Mouse Ear Swelling Test)法を応用した。このために、実施例3の組成物1〜5を使用し、比較群としてEGCGを使用した。
Example 5: Measurement of Scalp Inflammation Mitigation and Suppression Effect of Composition The MEST (Mouse Ear Swelling Test) method is applied to measure the effect of the composition to mitigate and inhibit scalp inflammation by stimulation with a hair dye. did. For this purpose, compositions 1 to 5 of Example 3 were used, and EGCG was used as a comparison group.
動物としては、6−8週齢の雌CF−1マウスを用いた。マウスは、約2週間の適応期間を経て、すべて7つのグループに分けられ、各グループあたり10匹とした。動物実験室は、20±2℃、湿度50±10%を維持しながら、12時間の周期で光を調節した。全体の実験期間にわたって動物食が供給され、水は自由に飲めるようにした。 As animals, 6-8 week old female CF-1 mice were used. The mice were all divided into 7 groups after an adaptation period of about 2 weeks, with 10 mice per group. The animal laboratory adjusted the light at a 12 hour period while maintaining 20 ± 2 ° C. and 50 ± 10% humidity. Animal food was provided over the entire experimental period and water was freely available.
マウスの腹部部位から毛を除去し、25μlのFreund’s complete adjuvant(FCA)を腹部皮膚内の真皮層に2回注射した。マウスの腹部皮膚の角質層を強力テープを用いて除去した後、100μlの染毛剤をマウスの腹部皮膚内に塗布して30分経過後、同量の前記組成物1〜5あるいは比較物質を皮膚に塗布した。3日後、同じ実験を繰り返した。実験を始めてから6日経過後、スウェリングされた耳(ear swelling)の厚さおよびスウェリングの発生頻度を測定した。
表4から明らかなように、本発明にかかる前記組成物を染毛剤と共に処理した場合、耳のスウェリングの頻度が顕著に減少したことが分かり、耳の厚さも有意に減少し、炎症を緩和させる効果があることを確認することができた。これにより、本発明にかかる組成物は、染毛剤による炎症を緩和させる効果があると判断することができる。 As can be seen from Table 4, when the composition according to the present invention was treated with a hair dye, it was found that the frequency of ear swelling was significantly reduced, the ear thickness was also significantly reduced, and inflammation was reduced. It was confirmed that there was an effect of mitigating. Thereby, it can be judged that the composition concerning this invention has the effect of relieving the inflammation by a hair dye.
実施例6:頭皮の痒み症
本発明にかかる組成物の痒み抑制効果をテストした。実施例3の組成物1〜5および比較物質(EGCG)の皮膚への適用を容易にするために、無毛マウスを用いた。無毛マウスは、すべて7週齢の雄を用い、各群あたり10匹とした。組成物1〜3あるいは比較物質100μlを、1日2回、5日間処理した後、痒み誘発物質(Compound48/80)を生理食塩水に1mg/mlの濃度で溶かし、真皮層内に注射した。注射後直ちに観察用檻に無毛マウスを入れた後、30分間ビデオで撮影し、後ろ足で痒みの部位を掻く回数を測定して数字で表示した。前足で掻いたり口で噛むような行動は除き、後ろ足で注射部位を掻く行動のみを痒み行動の指標と見なして測定し、測定結果を下記表5に示した。
表5から明らかなように、本発明にかかる実施例3の組成物1〜5で前処理した場合、掻く回数が減少し、痒みを抑制する効果があることを確認することができる。 As is clear from Table 5, it can be confirmed that when pre-treated with the compositions 1 to 5 of Example 3 according to the present invention, the number of scratches is reduced and it has the effect of suppressing stagnation.
実施例7:剤形物の製造
In vivo実験で全般的に優れた効果を示した前記組成物を、日常生活で実際の頭皮および毛髪に適用できるように様々な種類の剤形に製造した。
Example 7: Manufacture of dosage forms The compositions, which showed generally good effects in in vivo experiments, were prepared into various types of dosage forms so that they could be applied to actual scalp and hair in daily life.
7−1:下記表6の組成によるヘアトニックの製造
7−2:下記表7の組成によるヘアシャンプーの製造
7−3:下記表8の組成によるヘアリンスの製造
7−4:下記表9の組成によるヘアローションの製造
実施例8.脱毛防止効果(ヘアトニック)の評価
初期脱毛現象のある被検者20人を対象として脱毛防止効果に関する実験を12週進めた。前記実施例7の7−1の剤形例1および比較例1、比較例2のヘアトニックを、1日1回ずつ、12週間使用し、12週経過後、髪を洗う時に再度脱落毛を収集してその個数を数え、その結果を下記表10に示した。
表10から明らかなように、本発明にかかる剤形例1のヘアトニックで処理する場合、比較例1または2を処理した場合に比べて、脱落毛の個数が有意に減少することを確認した。 As is apparent from Table 10, when the hair tonic of the dosage form example 1 according to the present invention was treated, it was confirmed that the number of shed hairs was significantly reduced as compared with the case of treating the comparative example 1 or 2. .
実施例9:フケ生成防止および痒み症予防効果の評価
9−1:フケ防止効果の測定
前記実施例7の7−2のヘアシャンプー(剤形例2、比較例3、または比較例4)に対して、フケ生成防止効果を測定した。
Example 9: Evaluation of dandruff formation prevention and itch prevention effect 9-1: Measurement of dandruff prevention effect In 7-2 hair shampoo of Example 7 (formulation example 2, comparative example 3, or comparative example 4) On the other hand, the effect of preventing dandruff formation was measured.
フケが比較的多い男女10人を選定し、試験開始前に通常のシャンプーで洗髪して3日間累積したフケを採集し、採集されたフケの重量と、前記組成物(剤形例2)、サリチル酸(比較例3)またはEGCG(比較例4)が含有されたヘアシャンプー水で1ヶ月間洗髪して3日間累積したフケの重量とを比較評価した。 Select 10 men and women who have relatively large dandruff, wash the hair with regular shampoo before starting the test, collect the dandruff accumulated for 3 days, the weight of the collected dandruff, the composition (formulation example 2), The hair was washed with hair shampoo water containing salicylic acid (Comparative Example 3) or EGCG (Comparative Example 4) for 1 month, and the weight of dandruff accumulated for 3 days was comparatively evaluated.
この時、累積されたフケの採取は、被試験者の頭皮を、通常のシャンプー5g程度を用いて試験者に洗浄させた後、約2〜3リットルの水で洗い流すようにした。洗い流した水を、800マイクロの空隙大の濾過体で濾過後、濾過体位のフケの乾燥重量を測定し、次の式によりフケ減少率を求め、被試験者が感じるフケ改善効果をアンケート調査し、これを下記表11に示した。 At this time, in order to collect accumulated dandruff, the test subject's scalp was washed with about 2 to 3 liters of water after the test subject was washed with about 5 g of normal shampoo. The washed water is filtered through an 800 micron void filter, the dry weight of the dandruff is measured, and the rate of dandruff reduction is calculated using the following formula. This is shown in Table 11 below.
フケ減少率(%)=[(試験開始前のフケの重量(mg)−試験開始1ヶ月後のフケの重量(mg))/試験開始前のフケの重量(mg)]×100
表11から明らかなように、本発明にかかる剤形例2のヘアシャンプーで処理する場合、比較例3または4で処理した場合に比べて、フケ防止効果が有意に増加することを確認した。 As is apparent from Table 11, when treated with the hair shampoo of Formulation Example 2 according to the present invention, it was confirmed that the anti-dandruff effect was significantly increased as compared with the case treated with Comparative Example 3 or 4.
9−2:痒み症防止効果の評価
前記実施例7の7−2のヘアシャンプー(剤形例2、比較例3または比較例4)に対して、痒み症防止効果を測定した。
9-2: Evaluation of pruritus prevention effect The pruritus prevention effect was measured with respect to the hair shampoo of Example 7-7 (formulation example 2, comparative example 3 or comparative example 4).
普通痒みを多く感じる男女を選定し、剤形例2、比較例3または比較例4の製品を、各製品あたり10人ずつ、2日1回ずつ、8週間使用させた後、面談を通じて下記表12の評価基準に従って評価し、表13に評点の平均で示した。
表13から明らかなように、本発明にかかる剤形例2のヘアシャンプーで処理する場合、比較例3または4で処理した場合に比べて、フケ防止、頭皮の痒み抑制効果が有意に増加することを確認した。 As is apparent from Table 13, when treated with the hair shampoo of Formulation Example 2 according to the present invention, the effect of preventing dandruff and scalp itch is significantly increased as compared with the case of treating with Comparative Example 3 or 4. It was confirmed.
実施例10.使用感改善効果の評価
25〜50歳の女性20人を対象として、実施例7の7−2のヘアシャンプー(剤形例2、比較例3または比較例4)を一般的な使い方によって毛髪に使用し、乾燥30分後に感じられるつや、滑らかさ、くしけずり感に対する満足度を評価するようにした。また、12時間後に感じられるつや、滑らかさ、くしけずり感に対する満足度も評価するようにした。各参加者は、1週間の間隔で、3種の異なるシャンプーをすべて使用するが、どの種類のシャンプーであるか分からないようにした。
Example 10 Evaluation of Usability Improvement Effect For 20 women aged 25 to 50 years old, the hair shampoo of Example 7-2 (Formulation Example 2, Comparative Example 3 or Comparative Example 4) is applied to hair by general usage. It was used to evaluate the degree of satisfaction with gloss, smoothness, and squeaky feeling after 30 minutes of drying. In addition, the satisfaction with the gloss, smoothness, and squeaky feeling felt after 12 hours was also evaluated. Each participant used all three different shampoos at weekly intervals, but did not know what type of shampoo it was.
満足度の評価は、各項目に対して、最も高い水準は5、最も低い水準は1とし、5、4、3、2、1のうちの1つを選択させた。各項目あたりの評価点数の平均を比較し、下記表14に示した。使用直後にはすべてのシャンプーの満足度が全般的に高く、剤形例2のシャンプーを使用する場合、満足度が相対的に高かった。しかし、12時間経過後のつや、滑らかさおよびくしけずり感において、比較例3および4のシャンプーを使用した場合、満足感が顕著に減少したのに対し、剤形例2を使用した場合、満足感が非常に高い水準に維持された。したがって、本発明の組成物は、毛髪の満足的な触感を画期的に長時間維持させることが分かる。
Claims (5)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0009811 | 2010-02-03 | ||
KR1020100009811A KR101201524B1 (en) | 2010-02-03 | 2010-02-03 | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives |
PCT/KR2011/000654 WO2011096688A2 (en) | 2010-02-03 | 2011-01-31 | Composition for improving scalp and hair health comprising a dibenzo-p-dioxin derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013518875A JP2013518875A (en) | 2013-05-23 |
JP5694382B2 true JP5694382B2 (en) | 2015-04-01 |
Family
ID=44355936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012551913A Active JP5694382B2 (en) | 2010-02-03 | 2011-01-31 | Composition for preventing hair loss and promoting hair growth comprising a dibenzo-p-dioxin derivative |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5694382B2 (en) |
KR (1) | KR101201524B1 (en) |
WO (1) | WO2011096688A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2665620T3 (en) * | 2013-08-22 | 2018-04-26 | Lucas Meyer Cosmetics Canada Inc. | Anti-dandruff compositions, and methods of use thereof |
KR102050585B1 (en) * | 2017-07-21 | 2019-12-02 | 주식회사 보타메디 | Phlorotannin composition having inhibitory effect on induction of gray hair and promoting effect on induction of dark hair |
WO2019147044A1 (en) * | 2018-01-25 | 2019-08-01 | 주식회사 헤마스 | Composition for animal feed comprising phlorotannin as active ingredient and product for animal |
CN113194743A (en) * | 2018-12-05 | 2021-07-30 | 博塔医疗株式会社 | Composition for improving food flavor comprising brown algae polyphenol as effective ingredient |
KR102144990B1 (en) * | 2019-04-24 | 2020-08-14 | 한국과학기술연구원 | Acrylate compound, polymer formed from the acrylate compound, and polyacrylate film containing the polymer |
CN111018874B (en) * | 2019-11-25 | 2021-06-22 | 武汉华星光电半导体显示技术有限公司 | Hole transport material, preparation method thereof and organic light emitting diode device |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3652382B2 (en) * | 1994-04-11 | 2005-05-25 | 株式会社ナリス化粧品 | Testosterone-5α-reductase inhibitor |
KR100363112B1 (en) * | 2000-04-27 | 2002-12-05 | 벤트리 주식회사 | Novel Material Separated from Ecklonia cava, The Method for Extracting and Purifying the Same, And The Use Thereof for Antioxidants |
KR20020025358A (en) * | 2000-09-28 | 2002-04-04 | 이 행 우 | Composition for growing hair and method of preparation thereof |
JP2007131571A (en) * | 2005-11-10 | 2007-05-31 | Ichimaru Pharcos Co Ltd | Hair papilla cell proliferation enhancer |
JP2007217339A (en) * | 2006-02-16 | 2007-08-30 | Kanehatsu Foods Co Ltd | Anti-allergic substance |
KR100879558B1 (en) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | Compositions for skin protection and improvement of skin diseases containing the dibenzo-p-dioxine derivatives |
JP2010013429A (en) * | 2008-07-01 | 2010-01-21 | Takashi Suzuki | Scalp preparation for external use |
-
2010
- 2010-02-03 KR KR1020100009811A patent/KR101201524B1/en active IP Right Grant
-
2011
- 2011-01-31 JP JP2012551913A patent/JP5694382B2/en active Active
- 2011-01-31 WO PCT/KR2011/000654 patent/WO2011096688A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2011096688A3 (en) | 2012-01-05 |
JP2013518875A (en) | 2013-05-23 |
KR20110090174A (en) | 2011-08-10 |
WO2011096688A2 (en) | 2011-08-11 |
KR101201524B1 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5694382B2 (en) | Composition for preventing hair loss and promoting hair growth comprising a dibenzo-p-dioxin derivative | |
KR101402417B1 (en) | Anti-fungal composition comprising Filobasidium inhibiting substances derived from natural products | |
JP2022010412A (en) | Anti-aging agent | |
CN111973647A (en) | Preparation method of honeysuckle flower fermentation product and application of honeysuckle flower fermentation product in improving skin appearance and resisting aging | |
CN116509774B (en) | Anti-dandruff shampoo preparation containing sweet wormwood herb extract and preparation method thereof | |
KR20110085371A (en) | Cosmetic composition for improving scalp condition containing plant extracts | |
KR101064570B1 (en) | Composition for anti-irritancy comprising the extract of sophora flavescens, cinnamomum cassia blume, saururus chinensis and poncirus trifoliata | |
US20090170788A1 (en) | Novel use of 1, 2, 3, 4, 6-penta-o-galloyl-beta-d-glucose | |
US10335438B2 (en) | Camelid compound(s), composition(s) and method(s) | |
CN112245348A (en) | Skin-care cream and preparation method thereof | |
JP4906179B2 (en) | Topical skin preparation | |
Song et al. | Lactobacillus plantarum fermented Laminaria japonica alleviates UVB-induced epidermal photoinflammation via the Keap-1/Nrf2 pathway | |
KR101220508B1 (en) | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives | |
KR101252554B1 (en) | Composition capable of inhibiting sebum secretion | |
CN115969725A (en) | Skin care composition for soothing and repairing sensitive muscles and preparation method and application thereof | |
JP2000344653A (en) | Eraser for active oxygen and skin cosmetic | |
KR100777542B1 (en) | Anti-dandruff hair-care cosmetic composition | |
JPH03112912A (en) | Cosmetic composition | |
KR20210068936A (en) | Composition for improved atopy skin and skin moisturizing comprising natural extract | |
KR101177500B1 (en) | Hair growth stimulating composition | |
KR102676799B1 (en) | External Composition Comprising Natural Complex Extract for Improving Skin | |
KR101373714B1 (en) | Cosmetic composition promoting cornified envelope formation | |
CN108261346A (en) | A kind of lightening compositions and preparation method thereof | |
KR102224110B1 (en) | Composition for reducing the skin pore containing a substance related to regulation of ABH antigen expression | |
JP3584397B2 (en) | Hair restorer composition containing linacanthus eggplant extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140501 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5694382 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |